Vincent is the Founding Partner of 7G Bioventures. Prior to 7G Bioventures, Vincent was the Managing Director and Head of Global BioVentures for HillHouse Capital and a Partner with 6 Dimensions Capital. Vincent has led several series A investments including Viela (NASDAQ: VIE), iTeos (NASDAQ: ITOS), TScan (NASDAQ: TCRX), Erasca (NASDAQ: ERAS) and Tango (NASDAQ: BCTG).

Before 6 Dimensions, Vincent was Managing Director and Head of International Investments and Business Development for the Humanwell Healthcare Group (600079.SS), a Managing Director for the Burrill Life Science VC Fund, and a Vice President and Portfolio Manager at Franklin Templeton Investments.

Vincent received his PhD in Molecular Biology from the University of Stony Brook, an MBA from the Wharton Business School and a BS in Immunology and Microbiology from Fudan University.

Vincent has served as a board member for Viela (NASDAQ: VIE), Gossamer (NASDAQ: GOSS), Immunitas, Geneception, ShouTi, Angitia, Transcenta (6628.HK), Immvira, Elpiscience and LDX Prognostic, and as a board observer for iTeos (Nasdaq: ITOS) and Tango (NASDAQ: BCTG).